ArticleClinical drug investigation2021

Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.

George Gourzoulidis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.